J Biol Chem, Vol. 274, Issue 37, 26249-26258, September 10, 1999
Cloning and Expression of Bovine Neutrophil
-Defensins
BIOSYNTHETIC PROFILE DURING NEUTROPHILIC MATURATION AND
LOCALIZATION OF MATURE PEPTIDE TO NOVEL CYTOPLASMIC DENSE GRANULES*
Nannette Y.
Yount
,
Jun
Yuan
,
Alan
Tarver§,
Tammy
Castro¶,
Gill
Diamond¶,
Patti A.
Tran
,
Jack N.
Levy
,
Cheryl
McCullough
,
James S.
Cullor
,
Charles L.
Bevins**, and
Michael E.
Selsted

§§
From the Departments of
Pathology and

Microbiology and Molecular Genetics,
College of Medicine, University of California, Irvine, California
92697, the § Division of Genetics and Molecular Biology,
Children's Hospital of Philadelphia and Departments of Pediatrics and
Genetics, University of Pennsylvania School of Medicine, Philadelphia,
Pennsylvania 19104, the ¶ Department of Anatomy, Cell Biology and
Injury Sciences, University of Medicine and Dentistry of New Jersey,
Newark, New Jersey 07103, the
Department of Veterinary
Pathology, School of Veterinary Medicine, University of California,
Davis, California 95616, and the ** Department of Immunology, Cleveland
Clinic Foundation Research Institute, Cleveland, Ohio 44195
 |
ABSTRACT |
-Defensins are microbicidal peptides
implicated in host defense functions of phagocytic leukocytes and
certain surface epithelial cells. Here we investigated the genetic
structures and cellular expression of BNBD-4, -12, and -13, three
prototypic bovine neutrophil
-defensins. Characterization of the
corresponding cDNAs indicated that BNBD-4 (41 residues) derives
from a 63-amino acid prepropeptide and that BNBD-12 (38 residues) and
BNBD-13 (42 residues) derive from a common 60-amino acid precursor
(BNBD-12/13). The peptides were found to be encoded by two-exon genes
that are closely related to bovine epithelial
-defensin genes.
BNBD-4 and BNBD-12/13 mRNAs were most abundant in bone marrow, but
were expressed differentially in certain non-myeloid tissues. In
situ hybridization and immunohistochemical studies demonstrated
that BNBD-4 synthesis is completed early in myelopoiesis. BNBD-12 was
localized exclusively to the novel dense granules, organelles that also
contain precursors of cathelicidins, antimicrobial peptides that
undergo proteolytic processing during phagocytosis. In contrast to
cathelicidins, Western blot analyses revealed that mature
-defensins
are the predominant organellar form in myeloid cells. Stimulation of
neutrophils with phorbol myristate acetate induced secretion of
BNBD-12, indicating that it is co-secreted with pro-cathelicidins. The
exocytosis of BNBD-12 by activated neutrophils reveals different
mobilization pathways for myeloid
- and
-defensins.
 |
INTRODUCTION |
Polymorphonuclear leukocytes
(PMN1; neutrophils) provide
one of the first lines of host defense against invading microorganisms. In addition to their production of microbicidal reactive oxygen intermediates, PMNs also inactivate microorganisms by exposing them to
antimicrobial peptides and proteins in the phagolysosomal vacuole. In
recent years several classes of phagocyte-derived antimicrobial
peptides have been purified from mammalian phagocytes (reviewed in
Refs. 1-3). Similar molecules have also been isolated from specialized
epithelia (4-7), suggesting that antimicrobial peptides may play a
role in the intrinsic resistance of tissues to microbial invasion.
The cytoplasm of ruminant neutrophils is populated with unique, dense
(so-called large) granules that were reported to contain most of the cellular antimicrobial protein activity (8). Romeo, Gennaro, and co-workers purified from dense granules three cationic antimicrobial peptides termed bactenecins, peptides now
known to be members of the cathelicidin antimicrobial peptide family (9-11). Bovine neutrophil granules also contain
-defensins, a family represented by 13 cationic, tridisulfide-containing peptides containing 38-42 residues (12). Although
-defensins are similar in
conformation to
-defensins, the disulfide bonding patterns of the
two defensin families are distinct (13, 14) (Fig.
1). Neutrophil
-defensins have potent
antibacterial activities against Staphylococcus aureus and
Escherichia coli in vitro (12). In addition to their
abundant expression in neutrophils, related
-defensins are expressed
in the epithelium of bovine trachea (tracheal antimicrobial peptide, or
TAP; Ref. 4), tongue (lingual antimicrobial peptide, or LAP; Ref. 7),
and intestine (enteric
-defensin, or EBD; Ref. 15). Several
homologous peptides were also purified from chicken and turkey
leukocytes (16, 17), and members of the
-defensin gene family from
sheep (18), pig (19), and mouse (20, 21) have been characterized at the DNA level. Two human
-defensins were recently described. The first,
hBD-1, was isolated from plasma ultrafiltrate (22) and from urine,
plasma, and vaginal secretions (23), and hBD-1 mRNA was detected in
several epithelial tissues (24) including airway epithelium (25).
hBD-2, isolated from psoriatic skin, was microbicidal or microbistatic
against bacteria and yeast in vitro (26), and at least two
studies have demonstrated that hBD-2 expression is elevated in
inflammatory states (27, 28). Investigations of the functions of mouse
-defensins are likely to provide new insights into the role of these
peptides in host defense (20, 29, 30).

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 1.
Covalent structural comparison of - and -defensins. The
schematic shows the similar size and dissimilar cystine motifs of the
two myeloid defensin families. Single letters
indicate highly conserved amino acids. X denotes positions
that are more variable. The disulfide connectivities in the family
are 1-6, 2-4, and 3-5; in the family they are 1-5, 2-4, and
3-6.
|
|
Here we report studies on neutrophil
-defensin genes, their
expression during myelopoiesis, and the accumulation of
-defensin peptide in cytoplasmic organelles. The genes and cDNAs encoding three prototypical
-defensins, BNBD-4, -12, and -13, were cloned and
sequenced, demonstrating a high degree of similarity between bovine
neutrophil and epithelial
-defensins at the mRNA and protein levels. Expression of
-defensins in various tissues was assessed by
Northern blot analysis, and the pattern of expression during myelopoietic differentiation was determined by in situ
hybridization and immunohistochemical staining of neutrophils and
neutrophil progenitors. In addition, the organellar site of
-defensin stores in mature neutrophils was established by immunogold
electron microscopy. The extent of post-translational processing of the
peptide precursor in immature and mature neutrophilic cell populations
was determined, and studies were performed to establish the fate of
-defensin peptide during stimulation with phorbol myristate acetate.
 |
EXPERIMENTAL PROCEDURES |
Tissue Isolation--
Neutrophils were obtained from
anticoagulated whole blood of dairy cows as described previously (12).
RNA for cDNA library construction was obtained from calf bone
marrow curetted from femurs and flash frozen in liquid N2
within 2 h of sacrifice. Northern blot, primer extension, and RACE
analyses were carried out using bone marrow isolated from adults
animals as described (31). In situ hybridization studies
were performed on calf bone marrow cells. Leukocyte DNA was used for
genomic Southern hybridizations.
General Methods for Cloning and DNA
Characterization--
Oligonucleotide probes were end-labeled to a
specific activity of ~107 dpm/pmol using
[
-32P]ATP as described (31). Purified plasmid DNA was
sequenced from both strands using the dideoxy-chain termination method
(32). PCR products were incubated in a standard fill-in reaction and then subcloned as described (33).
-Defensin cDNAs--
BNBD-4 cDNAs were isolated from
a bone marrow cDNA library constructed in
gt10 (Genentech, South
San Francisco, CA). Approximately 1 × 106 recombinant
phage were screened using a degenerate oligonucleotide probe
(GCGGATCCRAARCAIGTICCIATYTGICKCAT) designed by back-translation of a
region conserved in
-defensins BNBD-2-6 and -10-12/13 (12). End-labeled oligonucleotides were hybridized to membranes at 55 °C
(34), which were washed in 5× SSC, 0.1% SDS at 56 °C. Of approximately 80 positive plaques, 40 were plaque purified and six were
subcloned into pGEM-7Zf+ (Promega, Madison, WI). The cDNA encoding
both BNBD-12 and BNBD-13 was amplified by reverse transcription-PCR.
The first strand of bone marrow cDNA was used as template, and the
oligonucleotides BNBD-12/3a (TGGTCCTCTAAGCTGTGGTA) and BNBD-10/1 s
(CCAGCATGAGGCTCCATCA) were used as PCR primers. The 5'-RACE protocol of
Frohman (35) was modified as described (15) using total RNA (5 µg)
from adult bovine bone marrow and the nested gene-specific primers
BNBD4/271a (CGCAGTTTCTGACTCCGCATTGG) and BNBD4/242a (CCGTGTGTTTGCCTTCATTTACT).
Genomic Cloning--
A bovine genomic library in EMBL-3
(CLONTECH, Palo Alto, CA) was screened with
32P-labeled TAP48a
(5'-CCAAGCAGACAGGACCAGGAAGAGGAGCGCGAGGAGCAGGTGATGGAGCCTCAT) as described (31). TAP-48a-positive plaques were rescreened at lower
phage density through tertiary screens until pure. Phage DNA was
isolated from liquid culture (36), and EcoRI restriction enzyme fragments of phage insert DNA were subcloned by ligation into the multiple cloning site of pBluescript II SK+ plasmid DNA (Stratagene). Preliminary sequence analysis indicated that two of the
phage clones encoded BNBD-4 and BNBD-12/13, and these were selected for
further analysis.
Sequence Alignments--
Sequence data were analyzed using
MacVector 6.0 (IBI, New Haven, CT) or Geneworks 2.4 (IntelliGenetics,
Mountain View, CA) software packages. cDNA and predicted amino acid
sequences were compared within and between species using the sequence
alignment function of Geneworks 2.4. cDNA and genomic sequences and
the predicted cDNA translation product were compared with the
GenBankTM data base using BLAST (37, 38).
Southern Blot Analysis--
Bovine genomic DNA was isolated from
leukocytes (4, 36) and digested to completion with restriction enzymes
(Life Technologies, Inc.) according to the supplier's recommendations.
DNA samples were size-fractionated by agarose gel electrophoresis,
blotted to a nylon membrane (Hybond N+, Amersham Pharmacia Biotech),
and incubated with a probe, BNBD-4/251a
(GGTGTGTTGAAGGGCGCAGTTTCTGACTCCGCATTGG) using standard
techniques (36, 39). The hybridization conditions were 40% (v/v)
formamide, 5× SSC, 5× Denhardt's (1× concentration = 0.02%
Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin), 1%
(w/v) SDS at 42 °C overnight, and the high stringency wash
conditions were 2× SSC, 0.1% SDS at 62 °C for 20 min (36). The
filter was then subjected to autoradiography at
70 °C in the
presence of a Cronex Lightening Plus intensifying screen (NEN Life
Science Products) for 4 weeks.
Northern Blot Analysis--
Total RNA was extracted and
subjected to Northern blot analysis as described (31). The
-defensin
probes were BNBD-4/251a (see above) and BNBD-12/239a
(GTTCTGTCGAAGGGCACAGTTTCTGTCTCCGCGTAGG). Labeled probes
were hybridized overnight to immobilized RNA in 37.5% (v/v) formamide,
5× SSC, 5× Denhardt's, 1% (w/v) SDS at 42 °C, and then washed at
high stringency in 0.1× SSC, 0.1% SDS at 57 °C for 30 min (36). A
bovine
-tubulin cDNA probe was used as a control for RNA
integrity (31). The filter was stripped of oligonucleotide label by
incubation in 0.1× SSC, 0.1% SDS at 70 °C for 30 min and exposed
to film to assure removal of probe prior to hybridization with another probe.
In Situ Hybridization--
Heparinized bovine bone marrow cells
were cytocentrifuged onto poly-L-lysine-coated slides,
fixed, and dehydrated as described previously (34).
UTP-digoxigenin-labeled sense and antisense riboprobes were transcribed
from linearized plasmid containing the full-length BNBD-4 cDNA
using T7 or Sp6 RNA polymerases (40), and hybridized to fixed cells as
described previously (34). RNA-RNA hybrids were detected with alkaline
phosphatase-conjugated anti-digoxigenin antibody and developed with
nitro blue tetrazolium (40).
Antibody Production--
Antibodies were prepared against
synthetic linearized (reduced and carboxymethylated) BNBD-12, and
separately against folded and oxidized peptide. Details of the BNBD-12
synthesis will be described elsewhere. Briefly, the peptide chain was
assembled using automated Fmoc
(N-(9-fluorenyl)methoxycarbonyl) solid phase synthesis, and
following acidolytic cleavage and deprotection of the peptide resin,
the linear peptide was purified by reversed phase HPLC. Five mg of
reduced peptide was oxidized by stirring a solution containing 100 µg/ml peptide in 0.1 M Tris acetate, pH 8.0, for 48 h in room air. Following oxidative folding, the peptide was purified to
homogeneity by RP-HPLC. The purified peptide was shown to be identical
to natural BNBD-12 by acid-urea PAGE, RP-HPLC, and matrix-assisted
laser desorption ionization/time of flight mass spectroscopy.
Linearized BNBD-12 was prepared by reducing 1 mg of the purified,
oxidized/folded peptide with DTT, followed by alkylation with
iodoacetic acid as described previously (41). The linearized,
S-carboxymethylated peptide was dialyzed exhaustively
against 5% acetic and lyophilized. Folded/oxidized (2.0 mg) and
linearized (1.0 mg) BNBD-12 preparations were individually conjugated
to an equal weight of crystallized ovalbumin (Sigma) in 20 mM sodium phosphate buffer, pH 7.4, containing 6.6 mM glutaraldehyde. The conjugation mixtures were stirred
for 4 h at room temperature, then quenched by addition of glycine
to 150 mM final concentration, dialyzed against water, and
lyophilized. New Zealand White rabbits were separately immunized with
the resulting conjugates to generate anti-native BNBD-12 or anti-linear
BNBD-12 antibodies. Antibody titers obtained from each rabbit were
greater than 1:10,000 as determined by enzyme-linked immunosorbent
assay. The IgG fraction of each antiserum preparation was generated
using DEAE Econo columns (Bio-Rad) per manufacturer's instructions.
Antisera or IgG preparations were used for immunocytochemistry,
immunogold electron microscopy, and Western blotting as indicated.
Immunohistochemistry--
Cytospin slides were prepared using
suspensions of peripheral blood leukocytes and suspensions of calf bone
marrow cells. Slides were blocked for 30 min with 5% normal goat serum
and incubated with anti-native BNBD-12 antibody at the indicated
dilutions at 8 °C for 18 h. Negative control incubations were
performed using preimmune serum or peptide-preabsorbed antiserum.
Slides were washed and developed using biotinylated goat anti-rabbit
IgG using a VectaStain avidin-biotin-glucose oxidase kit (Vector
Laboratories, Burlingame, CA) per the manufacturer's recommendations.
Nuclear Fast Red was used as counterstain.
Electron Microscopy--
Peripheral blood neutrophils were
prepared for transmission electron microscopy using standard methods.
Briefly, cells were fixed in 2% glutaraldehyde, 0.1 M
sodium cacodylate, pH 7.4, post-fixed in 1% osmium tetroxide, and
counterstained with uranyl acetate. Samples were then dehydrated in a
series of graded ethanols, immersed in propylene oxide, and embedded in
Epon 812/araldite resin. Sections (600-900 Å) were prepared using an
Ultracut E microtome (Reichert) and evaluated with a Zeiss 10A
transmission electron microscope. Cells were stained for peroxidase
prior to transmission electron microscopy. For immunogold labeling,
leukocytes were suspended in PBS and fixed by adding an equal volume of
8% paraformaldehyde, 10% sucrose, in PBS, pH 7.4. After 1 h at
room temperature, the suspension was washed three times with PBS
containing 5% sucrose, and then embedded in 10% gelatin, 5% sucrose
in PBS by centrifugation at 200 × g. The gelatin plug
was cut into small pieces, infiltrated with 2.3 M
sucrose/PBS overnight at 4 °C, mounted on grids, frozen, and stored
in liquid nitrogen. Thin sections were cut as described previously
(42), and incubated for 1 h with 1:10 anti-native BNBD-12 IgG as
primary antibody. The secondary antibody was goat anti-rabbit IgG
conjugated to 10 nm gold beads (Zymed Laboratories Inc.) and was used at 1:50 dilution. Preimmune rabbit serum was used in the primary incubation as a negative control.
Western Blot Analysis--
Peripheral blood leukocytes and fresh
bone marrow cells were suspended in Hanks' balanced salt solution
containing 2.5 mM MgCl2. Cell suspensions were
counted, pelleted by centrifugation, and snap-frozen. Some cell
preparations were treated for 10 min at 0 °C with 2 mM
diisopropyl fluorophosphate (DFP), a cell-permeable serine protease
inhibitor, as described previously (43) prior to freezing. Extracts of
DFP-treated or untreated cells were obtained by one of the following
methods. (i) A frozen cell pellet was immersed in a boiling water bath.
Simultaneously, 250 µl of preheated (~95 °C), DTT-containing
SDS-PAGE sample buffer (44) was added, the suspension was mixed and
boiled for 5 min. DNA in some samples was sheared with a 22-gauge
needle, and these samples were boiled once again for 5 min. (ii)
Alternatively, the cell pellet was suspended in 5-10 ml of ice-cold
10% acetic acid, briefly sonicated, and stirred for 18 h at
0 °C. The suspension was clarified by centrifugation at 27,000 × g for 20 min at 4 °C, and the supernatant was
lyophilized in aliquots of 0.5-1.0 × 107 cell
eq/tube. Lyophilized material was dissolved in DTT-containing SDS-PAGE
sample buffer, and boiled for 5 min. Immediately prior to
electrophoresis, DTT-reduced samples were alkylated with a 3 M excess of iodoacetic acid in the dark for 5-20 min, and
the alkylation reaction was quenched by addition of excess DTT. Samples were electrophoresed on Tricine-SDS gels containing 15% acrylamide (44), and electroblotted onto 0.22-µm nitrocellulose membranes (MSI,
Westborough, MA) using a semidry blotting apparatus. Lyophilized samples obtained by acid extraction were also analyzed by acid-urea (AU)-PAGE on 12.5% gels and transferred to nitrocellulose
membranes (45). For immunodetection of blots from SDS gels, the primary incubation employed 1:1000 or 1:5000 dilutions of anti-linear BNBD-12
IgG; for blots of AU gels, 1:3000 diluted anti-native BNBD-12 antiserum
was used. In all cases, the second antibody was 1:100,000 goat
anti-rabbit IgG antiserum conjugated to horseradish peroxidase. Blots
were developed by exposing x-ray film to the chemiluminescence signal
obtained using Ultra or Super Signal substrates (Pierce).
Neutrophil Activation--
Freshly prepared neutrophils (>95%)
were suspended in Hanks' balanced salt solution, pH 7.4, without
calcium, 2.5 mM MgCl2 to a cell density of
5 × 107 cells/ml. Suspensions were activated by
addition of phorbol myristate acetate (PMA) in 0.1% Me2SO
to a final concentration of 30 or 100 nM, and incubated
with gentle tumbling for 30 and 60 min at 37 °C. At the specified
intervals, cells were tested for viability by trypan blue exclusion
(>90% at each time point), and the incubation mixtures were
centrifuged at 234 × g for 15 min at 4 °C. The
supernatant was then removed, placed on ice, acidified with 10% acetic
acid, and lyophilized. Cell pellets were suspended in ice-cold 10%
acetic acid and sonicated for 15 s on ice. Sonicates were stirred
overnight at 8 °C, clarified by centrifugation, and the supernatant
samples were lyophilized. Supernatant and cell pellet extracts of
PMA-treated samples and controls were reduced and alkylated and
analyzed on SDS-PAGE Western blots as described above.
 |
RESULTS |
Characterization of cDNA and Genomic Clones--
To facilitate
studies on the temporal and tissue-specific patterns of neutrophil
-defensin expression, we initially isolated and characterized the
cDNA encoding BNBD-4. Six cDNA clones encoding BNBD-4 were
isolated from a bone marrow library screened with an oligonucleotide
corresponding to a 10-amino acid sequence conserved in
-defensins
BNBD-2-6 and -10-12/13 (12). The longest of these clones extended 19 nucleotides upstream of the putative initiation methionine, and the
125-nucleotide 3'-untranslated region contained a polyadenylation
consensus signal 35 nucleotides upstream of the poly(A) tail (Fig.
2). The cDNA encoding BNBD-12/13 was
obtained following reverse transcription-PCR of bone marrow mRNA
(see "Experimental Procedures") and confirmed by comparison with
the sequence of the corresponding genomic clone (see below).

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 2.
Nucleotide sequence of BNBD-4 and BNBD-12/13
cDNAs. The deduced amino acid sequence of the open reading
frame is shown in single-letter code. The
sequence of the mature peptide is underlined. Note that the
amino-terminal glutamine of BNBD-4 undergoes posttranslational
modification to pyroglutamate (12). The locations of the spliced
introns are indicated with vertical arrows. The
predicted translation start site (67) and the polyadenylation addition
signal (68) are in bold. A, BNBD-4. The sequence
represents a composite from the sequence of a gt10 cDNA clone
and four clones from 5'-RACE PCR analysis. The gt10 clone contained
the sequence spanning nucleotides 117 to 452. Two of the RACE clones
extend from the primer site (391) to the 5'-most nucleotide (+1), and
the other two suggest a start at +3. The GenBankTM accession number for
the BNBD-4 cDNA sequence is U36200. B, BNBD-12/13. The
sequence represents a composite from the genomic EMBL3 clone and
the reverse transcription-PCR product from bone marrow derived
mRNA. The inverted brackets indicate the sequence obtained from the
cDNA sequence, which spans the splice junction site. The
first four underlined residues (SGIS) correspond to the amino-terminal
tetrapeptide of BNBD-13; the vertical line at
Gly-23 indicates the amino-terminal residue of BNBD-12.
|
|
The BNBD-4 and -12/13 cDNAs predict precursors of 63 and 60 amino
acids, respectively, each containing an 18-22-residue segment containing a signal sequence. The mature BNBD-4, -12, and -13 peptides
are composed of the carboxyl-terminal 41, 38, and 42 residues of the
respective precursors (Figs. 2 and 3).
For both peptide precursors, the presumed translation start was implied by the presence of a Kozak consensus sequence just proximal to the AUG
(Fig. 2) and coding sequences for signal peptides, which are highly
similar to those in other epithelial
-defensin precursors (Fig. 3).
The 4-residue (SGIS) "pro-segment" in BNBD-12 is identical to that
of the first 4 amino acids of BNBD-13 previously isolated from
peripheral blood neutrophils, suggesting that BNBD-12 and -13 derive
from alternate processing of a common precursor.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 3.
Sequence comparisons of -defensin precursors and mature peptides. The
deduced precursors of BNBD-4, BNBD-12/13, bovine epithelial peptides
TAP, LAP, and EBD, and the human peptide hBD-2 were aligned with the
amino termini and cysteines in register. The mature peptide sequences
are separated from the signal peptide and pro-segment regions. Residues
predicted to be carboxyl termini of the signal sequences (69) are
boxed. The four amino acids (SGIS) present in mature BNBD-13
but absent in BNBD-12 are marked with asterisks. Sequence
similarities between peptides based on conservative amino acid
substitutions are highlighted. The calculated net charge
(Geneworks 2.5.1) of the -defensin precursors and mature peptides is
also shown .
|
|
Comparison of the bovine
-defensin precursors demonstrates that
leukocyte and epithelial peptides (EBD, TAP, and LAP) are similar in
size and sequence, with the greatest degree of sequence conservation
being in the signal peptide regions (Fig. 3). There is slightly more
sequence similarity among the respective myeloid and epithelial
-defensins than between them. On the other hand, hBD-2, a human
epithelial defensin, differs substantially from the bovine peptides
along the entire primary sequence (Fig. 3)
BNBD-4 and BNBD-12/13 genomic clones were isolated by screening a
genomic library to identify TAP-related sequences (4). Plasmid
subclones from two of the isolated phage clones were isolated, subcloned, and sequenced, revealing that they encoded BNBD-4 and BNBD-12/13. Comparison of the BNBD-4 genomic clone with the
corresponding cDNA sequence indicated that the gene consists of two
exons flanking an intron of 1486 nucleotides (Fig.
4, A and B;
GenBankTM accession number AF008307). 5'-RACE analyses established two
possible sites of transcription initiation for BNBD-4, either 133 or
135 nucleotides upstream of the initiation methionine. Analysis of the
5'-flanking region revealed a number of eukaryotic consensus sequences for putative cis-acting regulatory elements (46, 47). A
TATA box was identified at
22, and putative CAAT enhancer-binding protein (C/EBP;
147; Ref. 46) and polyoma enhancer binding protein-2/core binding factor (PEBP2/CBF;
100; Ref. 47)
response elements were also localized to this region.

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 4.
Genomic sequences of BNBD-4 and BNBD-12/13
exons and adjacent regions. Genomic sequences and deduced amino
acid sequences are shown. A, schematic of the BNBD-4 gene.
The intron/exon maps shown are indexed to a schematic of the spliced
transcript. Nearly identical organization is found for the BNBD-12
gene. B and C, BNBD-4 and BNBD-12/13 sequence
data. Exon sequences are capitalized; the introns and
flanking sequences are in lowercase; the deduced amino acid
sequences of the open reading frames are in single-letter code. The two identified transcription start sites for
BNBD-4 are indicated with arrowheads. The TATA sequence in
the 5'-flanking sequence of BNBD-4 is underlined. The
transcription start site of BNBD-12/13 was not determined, and thus the
sequence 5' to the initiating methionine is capitalized to
indicate uncertainty as to the 5' boundary of this exon. The
polyadenylation sites are boxed. The GenBankTM accession
number for BNBD-4 is AF008307, and those for BNBD-12/13 are AF105370
(exon 1) and AF105371 (exon 2).
|
|
Analysis of the BNBD-12/13 genomic clone confirmed the cDNA
analysis indicating that a single genomic sequence encodes both BNBD-12
and BNBD-13, and that it is very similar to BNBD-4 in organization and sequence (Fig. 4C). The genes were 88%
identical across coding and adjacent flanking regions. Interestingly,
although the size of the intron of the BNBD-12/13 gene (approximately
1.5 kilobases as estimated by restriction map analysis) was similar to
BNBD-4 gene, and despite highly similar sequence surrounding the
3'-splice acceptor site, the site of splicing differed by 12 nucleotides, corresponding exactly to the four additional residues (QRVR) present in the pro-segment of BNBD-4, which are lacking in
BNBD-12/13 (Figs. 3 and 4).
Southern analysis was performed to estimate the copy number of
the BNBD-4 gene. Under conditions of low stringency, Southern blots
probed with a
-defensin-specific oligonucleotide (BNBD-4 251a)
revealed multiple bands (data not shown), which likely indicate cross-hybridization to other
-defensin genes. At higher stringency, single bands were detected in lanes corresponding to each restriction digest (Fig. 5). While not conclusive,
these findings suggest that BNBD-4 is encoded by a single copy gene
among a family of closely related genomic sequences.

View larger version (79K):
[in this window]
[in a new window]
|
Fig. 5.
Southern blot hybridization analysis of the
BNBD-4 gene. Bovine genomic DNA (10 µg) was digested with
various restriction endonucleases and separated by size using gel
electrophoresis in a 1% agarose gel. The DNA was transferred to a
nylon membrane and hybridized with 32P-end-labeled
oligonucleotide BNBD4/251a as described under "Experimental
Procedures." Size standards are indicated at left.
|
|
Tissue Distribution of BNBD-4 and BNBD-12 mRNAs--
Myeloid
-defensins were initially isolated from bovine peripheral blood
neutrophils, but other possible sites of expression had not been
investigated. BNBD-4 and -12 mRNAs from various bovine tissues were
analyzed by Northern blot hybridization using gene-specific probes
designed as described under "Experimental Procedures." Abundant
mRNAs of ~0.5 kilobase encoding both peptides were identified in
bovine bone marrow (Fig. 6). BNBD-4
mRNA was also detected at lower levels in distal small intestine,
as well as trachea, lung, and spleen. The tissue specificity of BNBD-12
hybridizing signal was similar to that of BNBD-4, except for the
absence of BNBD-12 mRNA in lung and spleen. These data indicate
that neutrophil
-defensin genes are expressed in myeloid and
non-myeloid tissues.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 6.
Northern blot analysis of BNBD-4 gene
expression in bovine tissues. Total RNA (20 µg) extracted from
11 different tissues was resolved by electrophoresis in a standard
1.2% agarose/6% formaldehyde gel. The membrane was sequentially
hybridized under high stringency conditions with the
32P-end-labeled oligonucleotide BNBD4/251a
(BNBD-4), BNBD12/239a (BNBD-12), or -tubulin
cDNA (Tubulin).
|
|
BNBD-4 Gene Expression during Neutrophilic Myelopoiesis--
To
determine the myelopoietic stage at which
-defensin transcripts
first appear, we performed in situ hybridization experiments on bone marrow cell cytocentrifuge preparations using an antisense riboprobe corresponding to the full-length BNBD-4 cDNA. The probe hybridized strongly to promyelocytes and myelocytes, the earliest recognizable stages of neutrophilic myelopoiesis (Fig.
7, A-C). Faint hybridization
signals were detected in myeloblasts, and low levels of BNBD-4 mRNA
were detectable in metamyelocytes, but no signal was detectable
in neutrophilic bands or mature cells. Parallel hybridizations with
sense riboprobes were negative (Fig. 7D). These data
indicate that the BNBD-4 gene is selectively transcribed during the
early stages of granulocyte differentiation, but not at the terminal
stages of neutrophilic myelopoiesis or in mature neutrophils.

View larger version (75K):
[in this window]
[in a new window]
|
Fig. 7.
In situ hybridization
analysis of bovine bone marrow cells. Bone marrow cell cytospin
slides were prepared for in situ hybridization as described
under "Experimental Procedures." Bone marrow cells were identified
by standard criteria using bright field and phase contrast microscopy
(70) and are identified as follows: promyelocyte (PM) and
myelocyte (MC). Bar corresponds to 20 µM. Hybridization of bovine bone marrow preparations was
performed using antisense (A-C) and sense (D;
negative control) riboprobes corresponding to the full-length BNBD-4
cDNA. Positive hybridization was detected with alkaline
phosphatase-conjugated anti-digoxigenin antibody developed with nitro
blue tetrazolium and counterstained with nuclear fast red (40).
|
|
BNBD-12 Peptide Accumulation during Neutrophilic
Maturation--
Rabbit anti-BNBD-12 antibody was used to detect
-defensin peptide in fixed cytospins of peripheral blood leukocytes.
As shown in Fig. 8A, the
antibody stained the cytoplasm of mature neutrophils with a granular
pattern. BNBD-12 immunoreactivity was not detected in eosinophils or
mononuclear cells (Fig. 8A), and preimmune serum was
completely non-reactive with all cell types (Fig. 8B). Bone marrow cells were similarly stained with anti-BNBD-12 antibody. In
these experiments, all identifiable neutrophil progenitors were
immunopositive, but the granularity of staining was much finer than
observed with peripheral mature cells (Fig. 8C). Cells stained with BNBD-12-preabsorbed antibody were negative (Fig. 8D). These data demonstrate that peptide of native
conformation is detectable at all stages of neutrophil differentiation.
Further, it reveals a close correlation between
-defensin gene
transcription, assessed by in situ hybridization, and the
cytoplasmic accumulation of the translated product.

View larger version (95K):
[in this window]
[in a new window]
|
Fig. 8.
Immunohistochemical staining of BNBD-12.
Cytospin preparations of peripheral blood leukocytes (A and
B) and bone marrow cells (C and D)
were incubated with anti-BNBD-12 IgG (A and C) or
preimmune IgG (B and D). A, peripheral
leukocytes. All cells shown are neutrophils except the three
eosinophils (E). B, negative control staining of
leukocytes using preimmune IgG as the first antibody. C,
BNBD-12 immunoreactivity in neutrophilic precursors. A spectrum of
cells at different stages of maturation is shown. MB,
myeloblast; PM, promyelocyte; MC, myelocyte;
MMC, metamyelocyte; NB; neutrophilic band.
D, Staining of bone marrow cells using preimmune IgG as the
first antibody.
|
|
Localization of
-Defensins to Neutrophil Dense Granules--
A
novel feature of ruminant neutrophils is the presence of at least three
types of cytoplasmic granules (48), one of which, the large dense
granule (Fig. 9A), has been
shown previously to contain propeptide forms of cathelicidins (49). To
establish the organellar distribution of
-defensin in bovine
neutrophils, we performed immunogold localization studies on thin
sections of cells reacted with anti-BNBD-12 antibody. As shown in Fig. 9, gold particles localized exclusively over dense granules, but were
absent from sections over the other two granule types, the azurophil
and specific granules. The preimmune serum control incubation showed no
immunoreactivity (Fig. 9D).

View larger version (138K):
[in this window]
[in a new window]
|
Fig. 9.
Transmission electron microscopy.
A, bovine neutrophil stained for peroxidase. Azurophil
granules are the relatively rare, medium sized, oval, and darkly
staining cytoplasmic organelles. Specific granules are approximately
the same size as azurophil granules, round in shape, and have a
moderately coarse matrix. Dense granules are distinguished by their
large size, numerical abundance, and pale matrix material.
Bar = 1.0 µm; original magnification, ×11,150.
B, immunogold labeling of neutrophil sections incubated with
anti-BNBD-12 antibody reveals selective labeling of the abundant dense
granules. Bar = 1.0 µm; original magnification,
×14,200. C, enlarged perinuclear region of neutrophil
showing gold particle localization over dense granules. The smaller
specific granules (solid arrow) and azurophil
granules (hollow arrows) are not immunolabeled.
Bar = 0.2 µm; original magnification, ×57,500.
D, a region of cytoplasm analogous to that in C
incubated with preimmune antiserum as the primary antibody demonstrates
the specificity of anti-BNBD-12 antibody. Bar = 0.2 µm; original magnification, ×57,500.
|
|
Molecular Form of
-Defensins in Immature and Mature
Leukocytes--
Zanetti and co-workers (49) demonstrated that the
cathelicidins Bac5 and Bac7 are stored in bovine neutrophil dense
granules as inactive propeptides, and that their conversion to mature, microbicidal peptides requires proteolytic processing. To determine the
molecular form of
-defensins in neutrophil dense granules, we
analyzed extracts of neutrophils and bone marrow cells by Western blotting. Extracts were produced under various conditions to address and exclude the possibility of proteolytic degradation during extraction. To this end we used boiling-SDS or 10% acetic acid to
extract snap-frozen cell pellets that had been pretreated with DFP and
compared these extracts to those generated without DFP treatment. In
SDS-PAGE Western blots of DFP-treated or acid-extracted neutrophils,
anti-linear BNBD-12 IgG detected a single band that comigrated with
S-carboxymethylated BNBD-12 (Fig.
10A). The immunoreactivity was independent of the protocol employed for extraction, indicating that mature BNBD-12 is the predominant peptide form in neutrophils. An
identical result was obtained when bone marrow cell lysates were
analyzed by Western blot. As shown in Fig. 10B, anti-linear BNBD-12 antibody detected only a single band that comigrated with mature BNBD-12. As observed with neutrophil lysates, this pattern was
independent of the method of cell extraction. Because of their similar
sizes, BNBD-12 and BNBD-13 are not easily resolved on SDS-PAGE.
However, because all bovine native
-defensins migrate with unique
RF values in AU-PAGE (50), we utilized this
electrophoretic system to further analyze BNBD-12 immunoreactivity in
neutrophil and bone marrow lysates. As shown in Fig. 10C,
anti-native BNBD-12 antibody detected both BNBD-12 and -13 standards,
which were readily resolved in AU-PAGE. Analysis of PMN and bone marrow
cell acid extracts revealed the presence of only BNBD-12, irrespective
of whether the preparations were first treated with DFP. Taken
together, these data indicate that BNBD-12 is the predominant molecular form both in biosynthetically quiescent neutrophils and in
biosynthetically active bone marrow.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 10.
Western blot analysis of BNBD-12 in
neutrophils and bone marrow cells. A, immunoblot of PMN
extracts. A 15% Tricine-SDS gel was loaded with 0.5 µg each of
reduced, carboxymethylated BNBD-12 and -13 as standards, and four lanes
were each loaded with 2 × 106 cell eq of PMN extract.
Cells were either extracted directly by the method indicated, or first
treated with DFP as described under "Experimental Procedures."
Anti-linear BNBD-12 IgG was the primary antibody. The slower migrating
bands in the BNBD-12 and -13 lanes are peptide dimers that are
sometimes generated during the alkylation step. The band at ~15
kDa is unrelated to BNBD-12 since it also appears in blots developed
with only the secondary antibody. Molecular size markers are aprotinin
(6.5 kDa) and -lactalbumin (14.4 kDa). B, immunoblot of
bone marrow cells. Bone marrow cells were prepared, electrophoresed,
and tested for BNBD-12 immunoreactivity exactly as in panel A. Each lane was loaded with 1 × 106 cell
eq. BNBD-12 and -13 standards were 0.25 µg/lane. C,
acid-urea PAGE of PMN and bone marrow cell extracts. PMNs or bone
marrow cells (4 × 106 cell eq/lane) were extracted
with 10% acetic acid directly or following treatment with DFP as
indicated. Immunodetection was with anti-native BNBD-12 antiserum.
Standards were native BNBD-13 (2.0 µg) and BNBD-12 (0.5 µg).
|
|
Exocytosis of BNBD-12 by Activated Neutrophils--
Neutrophils
were stimulated with 30 or 100 nM PMA, a potent
secretagogue that selectively mobilizes secretory granules and vesicles. Western blot analysis was then used to determine whether BNBD-12 exocytosis occurs under these conditions, ones previously shown
to induce the secretion of Bac5 and Bac7 (51) (Fig.
11). No BNBD-12 was detected in any
incubation supernatant at the 30-min time point, and control cells (no
PMA) released no BNBD-12 throughout the 60-min experiment
(n = 5). After 60 min, BNBD-12 was detected in
supernatants at both PMA concentrations. Based on analysis of the
Western blot signals, we estimate that 15-20% of the cellular BNDD-12
is released and freely soluble.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 11.
Exocytosis of BNBD-12 from activated
neutrophils. Freshly obtained PMN were stimulated with PMA as
described under "Experimental Procedures." Supernatant samples
corresponding to 4 × 106 cells from each incubation
were reduced, alkylated, and electrophoresed on a 15% Tricine-SDS gel.
Pelleted cells from the corresponding incubations were extracted, and
1 × 106 cell eq of each sample were loaded.
Immunoblotting was performed with 1:3000 dilution of anti-linear
BNBD-12 IgG as described in the legend to Fig. 10.
|
|
 |
DISCUSSION |
-Defensins are the second family of tridisulfide host defense
peptides found in mammalian cells (52). Peptides comprising the first
such family,
-defensins, are genetically distinct from
-defensins, and the covalent structures of the two peptide families, including their disulfide motifs, are dissimilar (Fig. 1). The precursor structures of
-defensins and
-defensins are also quite different. Myeloid
-defensin precursors are 87-97 amino acids in
length (34). A 19-residue signal sequence is followed by a
39-45-residue polyanionic pro-segment, and the carboxyl-terminal 29-34 residues correspond to the mature defensin. While signal sequences occur in each of the known
-defensin precursors (Fig. 3),
an acidic pro-segment is absent. Instead, a stretch of 0-4 neutral
amino acids separates the signal and mature peptide sequences (Fig. 3).
The difference in
- and
-defensin precursor structures is of
interest, as it has been suggested that the anionic pro-segment in
-defensins neutralizes the cationic charge of the mature peptide during biosynthesis and organellar packaging to protect the producing cell from autocytotoxicity (53, 54). It is evident that charge balance
in the
-defensin precursor is not required since the net charge of
the initial translation product, as well as the mature peptides, is
strongly positive (Fig. 3). The structural differences of the two
defensin families suggest that they may be sorted and packaged by
distinct intracellular pathways.
Although the genetic organization and primary and disulfide structures
of the
- and
-defensins differ (Fig. 1), Zimmermann et
al. (14) reported that the peptide fold of BNBD-12 is very similar
to that of the
-defensins. The possible ancestral relationship of
the two defensin families was suggested by recent gene mapping data,
which place
- and
-defensin genes within a 150-kilobase segment
on human chromosome 8 (55). An additional clue may be inferred from the
isolation and structure determination of a "big defensin" from
horseshoe crab hemocytes (56). This peptide possesses the
-defensin
disulfide bonding pattern, but certain other sequence features are more
similar to the rat neutrophil
-defensin NP-2. Possibly this
invertebrate peptide is related to an ancestral peptide from which the
two mammalian defensin families have evolved.
As expected, BNBD-4 and -12/13 mRNAs were abundant in bone marrow
(Fig. 6), the predominant site of neutrophil production in adult
animals. In situ hybridization of bone marrow cells
demonstrated that BNBD-4 mRNA levels were highest in promyelocytes
and myelocytes, the myelopoietic stages during which dense granule
formation occurs (48). Lower BNBD-4 mRNA levels were detectable in
myeloblasts, and trace level signals were observed in some
metamyelocytes. However, no hybridization was observed in bands or
mature neutrophils, indicating that
-defensin synthesis is complete
at the time of release of the mature neutrophil into the peripheral
circulation. The overall profile of myeloid
-defensin mRNA
synthesis resembles the pattern of gene transcription observed for
neutrophil
-defensins (34, 57) except that peak
-defensin gene
expression appears to be slightly shifted toward more mature bone
marrow elements. This is consistent with the sequence of granulogenesis
in ruminant neutrophils, in which the appearance of azurophil granules
(the site of
-defensin storage in non-ruminant PMN) is followed
closely by the formation of
-defensin-containing dense granules
(48).
With rare exceptions, myeloid
-defensin expression has only been
noted in neutrophil granulocyte precursors of several mammals, or in
rabbit pulmonary macrophages. On the other hand, we detected mRNAs
for BNBD-4 and/or BNBD-12/13 in trachea, lung, spleen, and intestine (Fig. 6). Recently, Tarver et al. (15) cloned
the cDNA for BNBD-4 from bovine small intestine, and Ryan et
al. (58) demonstrated that bovine alveolar macrophages
express BNBD-4 and -5, as well as two "epithelial"
-defensins, TAP and EBD. Since mature neutrophils lack
-defensin
mRNAs, the mRNA levels in these tissues most likely represent
endogenous gene expression in these organs (15). However, it is
possible that neutrophils might be activated to express one or more
-defensin in certain tissues.
Comparison of the gene sequences of the epithelial (TAP, EBD) and
myeloid
-defensin genes may facilitate studies aimed at understanding their regulation and tissue-specific expression. Although
the 5'-flanking sequences (~750 nucleotides) of BNBD-4, TAP, and EBD
are 85% identical, analysis of this region for known transcription
factor-binding consensus sequences failed to identify motifs that
differentiate BNBD-4 from the epithelial
-defensins. Previous
studies have demonstrated induction of epithelial
-defensin expression in response to extracellular stimuli (7, 15, 59, 60).
Increased TAP mRNA levels are induced by exposure to endotoxin (59)
and tumor necrosis factor (61) and may be mediated in part by an
NF-
B recognition site in the TAP gene promoter region. Neither
BNBD-4 nor EBD have an NF-
B consensus binding sequence. However, all
three of these
-defensin genes contain putative C/EBP
recognition
sequences (46). C/EBP
, also known as NF-IL-6 (62), is a member of
the basic region-leucine zipper (
-zip) family of transcriptional
activators and functions to transactivate numerous genes in response to
lipopolysaccharide, interleukin-1
, and tumor necrosis factor (63).
Additionally, the BNBD-4 promoter region contains a PEBP2/CBF
recognition sequence (47) that is also present in the 5'-flanking
sequence of the EBD gene and in the intron of the TAP, EBD, and BNBD-4
genes. PEBP2/CBF has been implicated in the regulation of other
myeloid-specific genes. MyNF-1, a putative homolog of PEBP2/CBF
,
binds to and transactivates a PEBP2/CBF response element in the
myeloperoxidase and neutrophil elastase genes of murine promyelocytic
cells (47). Since BNBD-4 expression is tightly linked to the
phase of cellular differentiation (Fig. 7), we speculate that the
PEBP2/CBF response element may participate in the regulation of
-defensin gene expression during specific stages of neutrophilic
myelopoiesis. Future studies will be necessary to characterize the
function of these putative regulatory elements and will likely depend
on the availability of
-defensin-expressing myeloid cell lines.
It was previously shown that the bovine neutrophil dense granules,
organelles that distinguish ruminant neutrophils from leukocytes of
non-ruminant mammals, contain cationic antimicrobial peptides and
proteins not present in azurophil or specific granules (64). Conversely, dense granules lack azurophil or specific granule markers,
with the exception of lactoferrin (64). Gennaro and co-workers (10, 49,
51, 65) demonstrated that dense granule antimicrobial factors include
peptides termed bactenecins that are members of the cathelicidin
family. Data presented here (Fig. 9) demonstrate that
-defensins are
also stored in dense granules. Consistent with the immunolocalization
studies, we purified several known
-defensins from preparations of
purified dense granules, but detected none in mixed organelles depleted
of dense granules (data not shown). Therefore, since
-defensins and
bactenecins are stored together in dense granules, it is likely that
they are discharged simultaneously during neutrophil activation.
Although co-packaged in the dense granules, cathelicidins, but not
-defensins, are stored as inactive propeptides (49). Upon neutrophil
stimulation, the cathelicidins Bac5 and Bac7 are cleaved from their
respective propeptides and released extracellularly (51). Conversely,
data presented here indicate that
-defensins exist as fully
processed peptides in bovine neutrophils since anti-BNBD-12 antibody
detected only mature BNBD-12 in cell lysates (Fig. 10). This result was
obtained irrespective of the manner in which the cells were extracted,
i.e. with SDS versus 10% acetic acid, with or
without DFP pretreatment. This finding is consistent with the 10:1
abundance ratio of BNBD-12 to BNBD-13 in similarly extracted
neutrophils (12). Western blot analyses also indicate that the
transformation of the primary translation product to mature
-defensin occurs rapidly in the bone marrow, since we detected no
bands larger than that of the mature peptide in lysates rich in
neutrophil progenitors (Fig. 10, B and C). This suggests that the
-defensin precursor has a very short half-life, a feature that
differentiates
-defensin propeptide processing from Bac5 and Bac7,
which reside within the dense granules exclusively as propeptides
(49).
The demonstration that members of the cathelicidin and
-defensin
families are packaged in the same granule raises the possibility that
there may be important synergistic or even regulatory interactions that
may occur as these antimicrobial molecules are discharged from this
novel organelle. Activation of neutrophils with PMA (Fig. 11)
demonstrated that BNBD-12 is exocytosed under conditions that induce
secretion of Bac5 and Bac7. In contrast, Ganz (66) reported that human
neutrophils secrete very little
-defensin under similar conditions,
indicating that
- and
-defensins are mobilized differently from
their respective granules. Although we observed that the fraction of
BNBD-12 that was recovered from supernatants was less than the 50%
secretion of Bac5 and Bac7 previously reported (51), this difference
may be ascribed to differences in binding of the respective peptides to
the neutrophil surface after exocytosis, or to subtle differences in
experimental conditions. Nevertheless, the co-mobilization of these two
peptide families suggests that studies on their potential interactions, both within the phagosome and extracellularly, are merited.
 |
ACKNOWLEDGEMENTS |
We gratefully acknowledge the expert
technical assistance of Shirley Huang and Flavia Lega, and Dat Tran for
computational analysis of
-defensin precursors.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grants DK-08851 (to N. Y. Y.), AI-32738 and AI-32234
(to C. L. B.), HL53400 and USDA 9504034 (to G. D.), and
AI-22931 and AI-31696 (to M. E. S.), and by a grant from
Biosource Technologies, Inc. (to M. E. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF008307 (BNBD-4), AF105370 (BNBD-12), and AF105371
(BNBD-13).
§§
To whom correspondence should be addressed: Department of
Pathology, College of Medicine, University of California, Irvine, CA
92697-4800. E-mail: meselste@uci.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
PMN, polymorphonuclear leukocytes;
BNBD, bovine neutrophil
-defensin;
PCR, polymerase chain reaction;
RACE, rapid amplification of cDNA
ends;
PBS, phosphate-buffered saline;
DTT, dithiothreitol;
PAGE, polyacrylamide gel electrophoresis;
HPLC, high performance liquid
chromatography;
Tricine, N-tris(hydroxymethyl)methylglycine;
PMA, phorbol 12-myristate 13-acetate;
DFP, diisopropyl fluorophosphate;
TAP, tracheal antimicrobial peptide;
LAP, lingual antimicrobial
peptide;
EBD, enteric
-defensin.
 |
REFERENCES |
| 1.
|
Zanetti, M.,
Gennaro, R.,
and Romeo, D.
(1995)
FEBS Lett.
374,
1-5[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Lehrer, R. I.,
and Ganz, T.
(1996)
Ann. N. Y. Acad. Sci.
797,
228-239[Medline]
[Order article via Infotrieve]
|
| 3.
|
Boman, H. G.
(1998)
Scand. J Immunol.
48,
15-25[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Diamond, G.,
Zasloff, M.,
Eck, H.,
Brasseur, M.,
Maloy, W. L.,
and Bevins, C. L.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
3952-3956[Abstract/Free Full Text]
|
| 5.
|
Selsted, M. E.,
Miller, S. I.,
Henschen, A. H.,
and Ouellette, A. J.
(1992)
J. Cell Biol.
118,
929-936[Abstract/Free Full Text]
|
| 6.
|
Eisenhauer, P. B.,
Harwig, S. S. L.,
and Lehrer, R. I.
(1992)
Infect. Immun.
60,
3556-3565[Abstract/Free Full Text]
|
| 7.
|
Schonwetter, B. S.,
Stolzenberg, E. D.,
and Zasloff, M. A.
(1995)
Science
267,
1645-1648[Abstract/Free Full Text]
|
| 8.
|
Gennaro, R.,
Dolzani, L.,
and Romeo, D.
(1983)
Infect. Immun.
40,
684-690[Abstract/Free Full Text]
|
| 9.
|
Savoini, A.,
Marzari, R.,
Dolzani, L.,
Serrano, D.,
Graziosi, G.,
Gennaro, R.,
and Romeo, D.
(1984)
Antimicrob. Agents Chemother.
26,
405-407[Abstract/Free Full Text]
|
| 10.
|
Gennaro, R.,
Skerlavaj, B.,
and Romeo, D.
(1989)
Infect. Immun.
57,
3142-3146[Abstract/Free Full Text]
|
| 11.
|
Romeo, D.,
Skerlavaj, B.,
Bolognesi, M.,
and Gennaro, R.
(1988)
J. Biol. Chem.
263,
9573-9575[Abstract/Free Full Text]
|
| 12.
|
Selsted, M. E.,
Tang, Y.-Q.,
Morris, W. L.,
McGuire, P. A.,
Novotny, M. J.,
Smith, W.,
Henschen, A. H.,
and Cullor, J. S.
(1993)
J. Biol. Chem.
268,
6641-6648[Abstract/Free Full Text]
|
| 13.
|
Selsted, M. E.,
and Harwig, S. S. L.
(1989)
J. Biol. Chem.
264,
4003-4007[Abstract/Free Full Text]
|
| 14.
|
Zimmermann, G. R.,
Legault, P.,
Selsted, M. E.,
and Pardi, A.
(1995)
Biochemistry
34,
13663-13671[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Tarver, A. P.,
Clark, D. P.,
Diamond, G.,
Russell, J. P.,
Erdjument-Bromage, H.,
Tempst, P.,
Cohen, K. S.,
Jones, D. E.,
Sweeney, R. W.,
Wines, M.,
Hwang, S.,
and Bevins, C. L.
(1998)
Infect. Immun.
66,
1045-1056[Abstract/Free Full Text]
|
| 16.
|
Harwig, S. S. L.,
Swiderek, K. M.,
Kokryakov, V. N.,
Tan, L.,
Lee, T. D.,
Panyutich, E. A.,
Aleshina, G. M.,
Shamova, O. V.,
and Lehrer, R. I.
(1994)
FEBS Lett.
342,
281-285[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Evans, E. W.,
Beach, G. G.,
Wunderlich, J.,
and Harmon, B. G.
(1994)
J. Leukocyte Biol.
56,
661-665[Abstract]
|
| 18.
|
Mahoney, M. M.,
Lee, A. Y.,
Brezinski-Caliguri, D. J.,
and Huttner, K. M.
(1995)
FEBS Lett.
377,
519-522[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Zhang, G.,
Wu, H.,
Shi, J.,
Ganz, T.,
Ross, C. R.,
and Blecha, F.
(1998)
FEBS Lett.
424,
37-40[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Huttner, K. M.,
Kozak, C. A.,
and Bevins, C. L.
(1997)
FEBS Lett.
413,
45-49[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Morrison, G. M.,
Davidson, D. J.,
Kilanowski, F. M.,
Borthwick, D. W.,
Crook, K.,
Maxwell, A. I.,
Govan, J. R. W.,
and Dorin, J. R.
(1998)
Mamm. Genome
9,
453-457[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Bensch, K. W.,
Raida, M.,
Magert, H.-J.,
Schulz-Knappe, P.,
and Forssmann, W.-G.
(1995)
FEBS Lett.
368,
331-335[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Valore, E. V.,
Park, C. H.,
Quayle, A. J.,
Wiles, K. R.,
McCray, P. B., Jr.,
and Ganz, T.
(1998)
J. Clin. Invest.
101,
1633-1642[Medline]
[Order article via Infotrieve]
|
| 24.
|
Zhao, C.,
Wang, I.,
and Lehrer, R. I.
(1996)
FEBS Lett.
396,
319-322[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
McCray, P. B., Jr.,
and Bentley, L.
(1997)
Am. J. Respir. Cell Mol. Biol.
16,
343-349[Abstract]
|
| 26.
|
Harder, J.,
Bartels, J.,
Christophers, E.,
and Schroder, J.-M.
(1997)
Nature
387,
861 |